Thomas Gajewski to Antibodies, Monoclonal, Murine-Derived
This is a "connection" page, showing publications Thomas Gajewski has written about Antibodies, Monoclonal, Murine-Derived.
Connection Strength
0.073
-
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14.
Score: 0.053
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.020